Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against PTC Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is PTC Therapeutics, Inc. (PTCT) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether PTC has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On May 5, 2025, PTC issued a press release “announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients.” Although “[t]he study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability”, analysts who reviewed the data anticipated that the Company would likely need to conduct a Phase 3 study to better establish whether the treatment is actually slowing HD. On this news, PTC’s stock price fell $9.30 per share, or 18.62%, to close at $40.65 per share on May 5, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased PTC securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did PTC Therapeutics, Inc. (PTCT) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”